GL1X · GenesisL1 explorer

Research workbench

Kdr in complex with ligand sorafenib

Analyse Kdr in complex with ligand sorafenib in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3WZE
Type
protein
Length
298 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Vascular endothelial growth factor receptor 2
EC
2.7.10.1
UniProt
P35968
Ligands
BAX
Pockets
1 · best druggability 0.74

Structure

x-ray diffraction · 1 distinct chain · 40% helix, 17% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AVascular endothelial growth factor receptor 2 (EC 2.7.10.1)protein29840% helix, 17% strandP35968

Ligands and binding sites

  • BAX · 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide · ligand · chains A
  • ACT · Acetate ion · additive · chains A
  • DTT · 2,3-dihydroxy-1,4-dithiobutane · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16870.740.8075BAX

Modifications

Observed in the structure: 1 covalent (additive adduct).

Compared structures

  • 3WZE · KDR in complex with ligand sorafenib · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.